Overview
Lung fibrosis, characterized by excessive extracellular matrix deposition and tissue scarring, impairs lung function and can result from various etiologies including chronic infections, environmental exposures, and idiopathic causes. 1378Diagnosis
Clinical Presentation: Persistent cough, dyspnea, and decreased oxygen saturation 2.
Pulmonary Function Tests (PFTs): Reduced diffusing capacity, restrictive pattern, and decreased forced vital capacity (FVC) and forced expiratory volume in 1 second (FEV1) 2.
Imaging: High-resolution computed tomography (HRCT) showing characteristic reticular opacities, honeycombing, and traction bronchiectasis 2.
Bronchoalveolar Lavage (BAL): Elevated cellularity with increased macrophages and neutrophils 3.
Histopathology: Identification of fibrotic patterns such as usual interstitial pneumonia (UIP) on lung biopsy 5.Management
First-Line Treatments:
- Nintedanib: Off-label use, shown to improve 6-minute walk distance and oxygen saturation more significantly than pirfenidone 2.
- Pirfenidone: Effective in improving PFT parameters and oxygen saturation 2.
Adjunctive Therapies:
- DNA Repair Stimulation: Investigational approach targeting DNA repair mechanisms to potentially prevent fibrosis progression 1.
- Monitoring and Supportive Care: Regular PFTs, oxygen therapy, and management of comorbidities 2.Special Populations
Post-COVID-19 Syndrome: Specific consideration for patients with post-COVID lung fibrosis, where nintedanib and pirfenidone show efficacy but with differing adverse effect profiles 2.
Comorbidities: Increased vigilance for complications such as spontaneous pneumothorax in lung transplant recipients 4.Key Recommendations
Use Nintedanib or Pirfenidone for Post-COVID-19 Lung Fibrosis: Both drugs improve functional outcomes, with nintedanib showing greater benefits in 6MWT distance and oxygen saturation (Evidence: Moderate) 2.
Monitor Pulmonary Function Regularly: Employ PFTs to assess disease progression and treatment efficacy (Evidence: Expert opinion) 2.
Consider DNA Repair Strategies in Future Therapies: Promoting DNA repair mechanisms may offer preventive benefits against fibrosis progression (Evidence: Weak) 1.
Evaluate for Complications in Transplant Patients: Closely monitor for complications like spontaneous pneumothorax post-transplantation (Evidence: Expert opinion) 4.References
1 Ferrarelli LK. Promoting DNA repair to prevent fibrosis. Science signaling 2024. link
2 Kerget B, Çil G, Araz Ö, Alper F, Akgün M. Comparison of two antifibrotic treatments for lung fibrosis in post-COVID-19 syndrome: A randomized, prospective study. Medicina clinica 2023. link
3 Chyczewska E, Chyczewski L, Bańkowski E, Sułkowski S, Nikliński J. Stimulation of alveolar macrophages by BCG vaccine enhances the process of lung fibrosis induced by bleomycin. Folia histochemica et cytobiologica 1993. link
4 Spaggiari L, Rusca M, Carbognani P, Cattelani L, Rossini E, Paolucci R et al.. Contralateral spontaneous pneumothorax after single lung transplantation for fibrosis. Acta bio-medica de L'Ateneo parmense : organo della Societa di medicina e scienze naturali di Parma 1993. link
5 Bondi A, Mancini AM, Baldini N. Occurrence of different types of contractile cells in some lung fibrosis. Applied pathology 1983. link
6 Bashey RI, Herold RA, Jimenez SA. Biochemical characterization of collagens and of a non-collagenous protein synthesized by guinea pig lung fibroblasts in culture. Connective tissue research 1983. link
7 Johnson NF, Wagner JC. A study by electron microscopy of the effects of chrysotile and man-made mineral fibres on rat lungs. IARC scientific publications 1980. link
8 Eskenasy A, Ionescu J, Petrescu A, Lutescu L. Experimental viral lung fibrosis. Quantitative study of the relationships between cell accumulations and fibrillogenesis. Virologie 1976. link